DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.77
+0.06 (0.78%)
Mar 4, 2026, 4:00 PM EST - Market closed
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,140,214
Market Cap
416.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Autolus Therapeutics | 650 |
| Absci | 157 |
| Century Therapeutics | 150 |
| Enanta Pharmaceuticals | 120 |
| Aura Biosciences | 109 |
| Keros Therapeutics | 82 |
| Armata Pharmaceuticals | 60 |
DMAC News
- 8 days ago - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
- 6 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire
- 3 months ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 4 months ago - DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 4 months ago - DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 - Business Wire
- 5 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire